Cell Reports· 2026Q1
Contextual control of CD8+ T cell priming by dendritic cell subsets in tumor and inflammatory microenvironments
- 2citations
- Q1SCImago
- 2026year
Short summary
Migratory type 1 dendritic cells (migDC1s) exhibit superior cross-presentation machinery and CD8+ T cell priming capacity compared to lymph node-resident type 1 dendritic cells (resDC1s), particularly in tumor microenvironments.
AI-generated from the title and abstract; the full text is not read.
Key points
- Tumor antigen is more widely distributed among lymph node dendritic cells than skin-derived antigen.
- Migratory type 1 dendritic cells (migDC1s) express higher levels of cross-presentation machinery than lymph node-resident type 1 dendritic cells (resDC1s).
- MigDC1s demonstrate superior per-cell cross-presentation and CD8+ T cell proliferation induction compared to resDC1s.
- Antigen access and cell-specific cross-presentation efficiency together predict CD8+ T cell priming quality.
AI-generated from the title and abstract; the full text is not read.
Abstract
Migratory and lymph node-resident dendritic cells occupy distinct niches and drive T cell activation during infection, vaccination, and cancer. How tissue context and dendritic cell subset-specific transcriptional programs integrate to shape CD8 + T cell priming remains incompletely defined. Using fluorescent antigen, we track antigen distribution, dendritic cell transcriptional programming, and cross-presentation across tumor, inflamed, and steady-state tissues. Tumor antigen is more widely distributed among lymph node dendritic cells than skin-derived antigen. Migratory type 1 dendritic cells display higher expression of cross-presentation machinery and superior per-cell cross-presentation and induction of CD8 + T cell proliferation compared to lymph node-resident type 1 dendritic cells. Ultimately, antigen access and cell-specific cross-presentation efficiency together predict the quality of CD8 + T cell priming. These results identify migratory type 1 dendritic cells as central mediators of antitumor CD8 + T cell responses and support therapeutic strategies that augment the efficiency of resident dendritic cell cross-presentation.
The authors' abstract, as published at the source. Cell Reports, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
ImmunologyImmunology and Microbiology